Societe Generale’s Vertex Pharmaceuticals VRTX Stock Holding History

Societe Generale’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$17K	Buy	+12,000	New	+$1.04M	﹤0.01%	2516

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Societe Generale's VRTX Position: Q2 2016 in Review

Societe Generale opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2016: 19,068 shares worth $1.64M. The stake represents 0.01% of the portfolio and ranks #972 among its holdings.

482 funds tracked by Wall St. Rank hold VRTX as of Q2 2016.

Societe Generale held 19,068 shares of Vertex Pharmaceuticals worth $1.64M as of Q2 2016.
Vertex Pharmaceuticals was a new Societe Generale position in Q2 2016.
Vertex Pharmaceuticals made up 0.01% of Societe Generale's portfolio in Q2 2016, its #972 holding.
482 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.